Progressive multifocal leukoencephalopathy in Finland: a cross-sectional registry study.

J Neurol · 2019 · PMC6373365 · PMID 30612143

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

No predisposing drug showed a trend associated with this, save for alemtuzumab, the use of which peaked in 2010 and trailed off towards the end of the study period (it received an indication for MS in Finland only at the end of 2013).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.